2010
Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
Abstract: PurposeThe control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT3) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) contai…
Search citation statements
Paper Sections
Select...
18
5
5
1
Citation Types
1
19
0
1
Year Published
Range
2011
2022
Publication Types
Select...
24
1
Relationship
3
22
Authors
Journals
Cited by 25 publications
(21 citation statements)
References 30 publications
1
19
0
1
Smart CitationsHow the paper below cites the one you are viewing
“…The present study supported these findings. Thus, the efficacy of single iv doses of 0.25 mg palonosetron in the control of CINV during MEC treatment previously reported for a single cycle in this clinical setting [ 20 ] has been confirmed for up to four repeated and consecutive cycles of MEC in the absence of any safety concerns. This also confirms, in hematological patients, the maintenance of the antiemetic efficacy of palonosetron over several cycles that has been reported in other clinical settings [ 10 , 17 ].…”
Section: Discussion
supporting
confidence: 52%
Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy
Leukemia & Lymphoma
Self Cite
Abstract